Ann: Annual Report to Shareholders, page-9

Perhaps the date being earlier than usual.

Normally the AGM ,in recent years anyway, is held late November. Last mid November AGM was back in 2017.

If I'm a CEO waiting on an outcome , I would hold it as late as possible.


It's a confident move - Si knows where the cycle is up to- his comments in the annual report

Looking Ahead: A Transformative Year Awaits
As we approach 2025, I believe Mesoblast is on the verge of gaining a first approval in the U.S. which will
be transformative for our company. With an approval from FDA potentially just months away, and our plans
for commercialization in train, we are closer than ever to achieving our goal of making a meaningful difference in
the lives of children suffering from acute steroid-refractory GvHD

Note Si uses "I" not we, it is a personal belief. Then the use of "in train" meaning it's happening, it's on the move


2023 AGM - We believe we remain close to achieving our objective of gaining first FDA approval for remestemcel-L for both
children with SR-aGVHD and adults with this devastating disease


For Si to swap out we for I , let's presume it his ego talking




I hope so , wonder what he's all chuffed about?




Reg